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Injection of sterile aqueous preparations of the peptidoglycan-polysaccharide of group A streptococci
(PG-APS) produces chronic inflammation in several animal models. Chronic bacterial infection may be
involved in some aspects of the pathogenesis of inflammation associated with the accumulation of PG-APS.
Accordingly, the effect of PG-APS on human neutrophil (polymorphonuclear leukocyte [PMN]) bactericidal
activity was studied with the supposition that this interaction may contribute to the inflammation observed.
Concentrations of PG-APS greater than 10 ,ug/ml inhibited the ability of PMNs to kill Staphylococcus aureus.
This inhibition was not due to a cytotoxic effect of PG-APS on PMNs, nor did PG-APS inhibit PMN metabolism
required for the formation of microbicidal oxygen reduction products. PG-APS concentrations of 10 ,ig/ml or
greater in the presence of 10% normal serum inhibited the attachment of bacteria to PMNs by 49% as
compared with control cell populations. The concentrations of PG-APS required to inhibit uptake of
Staphylococcus aureus were identical to those required for inhibition of PMN bactericidal activity. This
inhibition did not occur in the presence of serum-free medium or medium with sera that had been heated to
inactivate complement. These results show that PG-APS interacts with serum to inhibit PMN-mediated killing
of S. aureus, most probably by interfering with bacterial uptake.
The cell walls of streptococci consist of covalently bound
polymers of peptidoglycan and group-specific polysaccha-
ride (12). Parenteral injection of animals with sterile aqueous
preparations of the peptidoglycan-polysaccharide of group A
streptococci (PG-APS) can produce chronic inflammation
(5-7, 25). In recent work we have shown that PG-APS
exposed to serum may stimulate formation of polymorpho-
nuclear leukocyte (PMN) oxygen reduction products (1),
which may relate to the pathogenicity of this substance (13).
Peptidoglycan covalently bound to a polysaccharide is
common to most bacteria, and the capacity to produce
inflammation is not confined to cell walls from group A
streptococci (24). Streptococcus mitis and Streptococcus
sanguis are important components of early supragingival
plaque (28) and have also been demonstrated to be present in
significant concentrations in subgingival plaque in periodon-
tal pockets (8). Cell walls isolated from S. mitis and S.
sanguis, as well as PG-APS, injected into the gingiva of rats
produce lesions consistent with periodontitis (11). There is
no significant difference in the inflammatory reaction among
cell wall preparations from these bacteria (11).
Periodontitis is a complex illness, but several lines of
evidence suggest that hereditary (e.g., cyclic neutropenia [3]
or acquired (2, 15, 17, 26) defects in phagocyte function may
exacerbate this process. Shurin and co-workers (26) have
reported that sonic extracts and culture media of capnocyto-
phaga, a bacterium commonly isolated from diseased peri-
odontal tissue, contain a dialyzable substance that interferes
with normal PMN migration. These investigators suggested
that acquisition of this organism and its interference with
PMN function might be important in the development of
periodontal disease.
Because of the potential importance of streptococci in
periodontal disease, we investigated the effect of PG-APS on
the bactericidal and phagocytic function of normal human
* Corresponding author.
PMNs. Our results show that PG-APS inhibits PMN-mediat-
ed killing of Staphylococcus aureus, most probably by
interfering with phagocytic mechanisms.
(Parts of this work were presented at the 61st General
Session of the American Association for Dental Research
and the 20th Interscience Conference on Antimicrobial
Agents and Chemotherapy, September 1980, New Orleans,
La.)
MATERIALS AND METHODS
Reagents. [1-14C]glucose and [14C]uracil were obtained
from New England Nuclear Corp. (Boston, Mass.). Zymo-
san (Sigma Chemical Co., St. Louis, Mo.) was freshly
prepared in bicarbonate-buffered (pH 7.4) Hanks balanced
salt solution (HBSS) at a concentration of 50 mg/ml before
use each day. Dimethyl sulfoxide was obtained from Sigma.
Phorbol myristate acetate (PMA) was purchased from Sig-
ma, dissolved in dimethyl sulfoxide to a concentration of 1
mglml, and frozen at -20°C. Fresh samples were thawed
before use each day. Previous work has shown that dimethyl
sulfoxide in the concentration used does not interfere with
the assays employed or cell survival (23).
Bacterial cell wall preparation. The details of the bacterial
cell wall preparation have been described (9). Briefly, group
A, type 3, strain D-58 streptococci were grown in Todd-
Hewitt broth (BBL Microbiology Systems, Cockeysville,
Md.) at 37°C to early-stationary phase in a Virtis fermentor
(Virtis Co., Gardiner, N.Y.). The cells were collected and
washed in a Pellicon filtration unit (Millipore Corp., Bed-
ford, Mass.) and disrupted in a Braun shaker (Bronwell
Scientific Co., Rochester, N.Y.). Cell walls were collected
by differential centrifugation, treated with trypsin, RNase,
papain, and chloroform-methanol, and washed five times.
Cell wall fragments were prepared by suspension in phos-
phate-buffered saline (pH 7.2) and subjected to sonic treat-
ment for 70 min in a Branson model 350 sonifier (Branson
Sonic Power Co., Danbury, Conn.). After sonication the
walls were passed through a 0.45-,um filter (Millipore Corp.,
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TABLE 1. Dose effect of PG-APS on PMN bactericidal activitya
PG-APS dose % CFU reduction (mean ± SD) at:
(jig/ml) 30 min 60 min 90 min
100 32 15 39 ± 16 40 ± 1.5
50 7±4 30±12 16±27c
25d -22 + lod 20 ± 18b 27 ± 29C
10 19 15 31 ± 21 57 ± 15
1 43 20 58 ± 4 74 ± 13
PMN control 23 ± 24 56 ± 25 67 ± 12
a Bacteria were incubated with PMNs at a 10:1 particle-to-cell ratio. The
bacterial control was 1.6 ± 1.0 x 107 CFU at 30 min and 2.4 ± 1.50 x 107 CFU
at 90 min (n = 3). Normal serum (10%) was included in all preparations.
Individual experiments were performed in duplicate, and results are the mean
and standard deviation of three separate experiments.
bSignificant difference (P < 0.025) compared with the PMN control.
' Significant difference (P < 0.05) compared with the PMN control.
d These results were obtained in separate experiments by using a 25 ,ug dose
of PG-APS. At 30 min, growth of bacteria was observed relative to the PMN
control such that preparations incubated with PG-APS had 122 ± 10% the
colonies of the bacterial control (-22% CFU reduction).
Bedford, Mass.), and the concentrations of rhamnose, N-
acetyl glucosamine, and N-acetyl muramic acid were mea-
sured by gas chromatography. Sterility was confirmed by
culture on blood agar plates.
PMN separation. Heparinized venous blood from normal
human donors was separated on Plasmagel (Roger Bellon
Laboratories, Neuilly, France), and a PMN-rich fraction
was obtained by Ficoll-Hypaque gradient centrifugation,
followed by dextran sedimentation and hypotonic lysis of the
erythrocytes as previously described (22). The final prepara-
tion contained 98% PMNs, and 98% of the PMNs were
viable as determined by trypan blue dye exclusion. In all
phagocytic and metabolic assays, except as noted below, the
final PMN concentration was 5.0 x 106 PMN per ml, and the
suspending medium was HBSS.
Preparation of serum and opsonization of bacteria. Fresh
serum was obtained from the clotted blood of normal AB
donors and stored at -70°C. S. aureus 502A cells were
grown in overnight culture in tryptic soy broth with or
without [14C]uracil as described previously (22). Opsoniza-
tion of the bacteria was achieved by incubating the particles
in 50% serum for 30 min at 37°C. The opsonized particles
were washed twice. In experiments with zymosan, final
suspensions contained ca. 100 particles per PMN. Heat-
inactivated serum was prepared by heating at 56°C for 30
min.
Measurement of oxygen consumption. Oxygen consump-
tion of cell suspensions containing 5 x 106 PMNs per ml in
HBSS was measured in the chamber of a Clark oxygen
electrode (Oxygen Monitor; Yellow Springs Instrument Co.,
Yellow Springs, Ohio) for 15 min at 37°C (22). Results are
expressed as the maximal rate of 02 consumption per
minute.
Measurement of [1-'4C]glucose oxidation. The conversion
of [1-14C]glucose to 14CO2 by PMNs for 30 min at 37°C in a
rubber-stoppered glass flask was employed as a measure of
the oxidation of glucose via the hexose monophosphate
shunt (22). 14CO2 was collected in alkali and measured in a
liquid scintillation counter (22).
Measurement of antimicrobial activity. S. aureus cells
grown on gonococcal-base broth (Difco Laboratories, De-
troit, Mich.) agar plates were washed and resuspended in
HBSS to 2.5 x 108 organisms per ml by using a Petroff-
Hauser counting chamber. An amount of 2.5 x 106 PMNs
per ml was preincubated with PG-APS or HBSS for 30 min at
37°C on a rotating rack. To initiate the experiment, 10%
serum and S. aureus (a 10:1 bacteria-to-cell ratio) were
added to the cell suspension into a final volume of 1.0 ml.
Samples were taken at 0, 30, 60, and 90 min, plated, and
incubated at 37°C overnight. The surviving colonies were
counted, and the percentage of bacteria killed was calculated
(4).
Measurement of attachment of '4C-labeled S. aureus. Sus-
pensions of 2.5 x 106 PMNs per ml were preincubated with
up to 100 ,ug of PG-APS per ml at 37°C for 30 min on a
rotating rack (12 rpm). 14C-labeled S. aureus cells in the
presence and absence of 10% serum were added to the cell
suspensions. Suspensions were incubated for 30 min, centri-
fuged, and washed twice with an ice-cold stop-wash solution
of 2 mM NaF, fetal calf serum, and HBSS (22). The
phagocyte-associated radioactive counts in suspension were
quantitated in a liquid scintillation counter.
Statistics. The statistical analysis employed was the Stu-
dent's t test when more than three experiments were per-
formed. Differences between control and experimental prep-
arations were considered to be significant at P < 0.05.
RESULTS
Effect of PG-APS on the ability of PMNs to kill bacteria.
The primary function of the PMN is to protect the host from
bacterial infection. Previous studies with S. aureus have
suggested that peptidoglycan is a critical molecule for opso-
nization of intact organisms (19, 29, 30). Alternatively, both
staphylococcal and streptococcal peptidoglycans have been
reported to interfere with cellular function (16, 27). We
investigated the effect of PG-APS on the ability of PMNs to
kill bacteria. Concentrations of PG-APS greater than 10 ,ug/
ml inhibited the ability of PMNs to kill S. aureus (Table 1).
PMNs incubated with 50 and 100 ,ug of PG-APS per ml





A 25 jg/ml PG-APS
O PMN control
0 30 60 90 120
MINUTES
FIG. 1. Changes in survival of S. aureus (CFU per milliliter) in
preparations with bacteria alone and with PMNs and PG-APS.
Points represent the mean of duplicate preparations. This experi-
ment is typical of three others.
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after 90 min, respectively, as compared with a 67 ± 12%
reduction in CFU by unexposed cells. Figure 1 represents a
typical experiment, showing the effects of PG-APS on PMN
bactericidal function over 120 min.
To rule out the possibility that PG-APS was toxic to the
PMNs, trypan blue exclusion tests for cell viability were
performed at 30, 60, 90, and 120 min. At all times, cell
viability was greater than 97%.
Effect of PG-APS on zymosan and PMA stimulation ofPMN
oxidative metabolism. A possible mechanism by which PG-
APS could inhibit PMN bactericidal activity is through
inhibition of the oxidative metabolism required for formation
of microbicidal oxygen reduction products. Although PG-
APS in the presence of serum triggers formation of oxygen
reduction products (13), the magnitude of stimulation of
oxidative metabolism by another agent might be reduced in
the presence of PG-APS.
PMNs were preincubated with 1.0 to 100 ,ug of PG-APS
per ml for 30 min, and the experiments were initiated with
the addition of zymosan and 10% normal serum (Fig. 2). PG-
APS concentrations of 10 ,ug/ml and greater inhibited zymo-
san stimulation of oxygen consumption. Similar concentra-
tions of PG-APS inhibited zymosan-stimulated glucose
oxidation by 30 to 50% (data not shown). Several interpreta-
tions of these results are possible, but it seems likely that
opsonized PG-APS interfered with the binding ofzymosan to
PMNs, at least part of which is complement dependent (21).
To insure that PG-APS had no adverse effect on PMN 02
metabolism itself, we studied the effects of PG-APS on cells
triggered by PMA, whose activity depends neither on serum
opsonins nor on immunoglobulin or complement receptors.
Cell suspensions were incubated with 50 ,ug of PG-APS per
ml for 30 min, 100 ng of PMA per ml and 10% serum were
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FIG. 2. Dose-response curve of PG-APS and 10% normal serum
on zymosan stimulation of PMN 02 consumption. Bars represent
the mean and brackets represent the standard deviation of three
experiments. Experiments were performed in duplicate.




With PMA (control)'.................. ............ 13,922
With PMA + PG-APS (50 jig/ml) ................. 13,811
a Normal serum (10%) was added to the systems.
b Results are the mean of two separate experiments.
' PMA was used at a concentration of 100 ng/ml.
tion of PMNs was not inhibited by pretreatment of cells with
PG-APS (Table 2).
Effect of PG-APS on binding of 14C-labeled S. aureus. To
more directly define the mechanism of PG-APS inhibition of
PMN bactericidal activity, we investigated the effect of PG-
APS on binding of radiolabeled S. aureus to PMNs in the
presence of 10o serum. PG-APS concentrations of 10 jig/ml
or greater inhibited attachment of bacteria to PMNs by 49%
(P < 0.05), as compared with control cell suspensions (Fig. 3
and 4). This dose-response curve was similar to that for
inhibition of PMN bactericidal activity.
The inhibition of attachment of bacteria to PMNs that was
observed may have resulted from two possible events. First,
via activation of the alternate complement pathway (10), PG-
APS could have depleted the serum complement compo-
nents necessary for opsonization of the S. aureus. Alternate-
ly, PG-APS may bind C3b and compete with the bacteria for
C3b-binding sites on the PMN membrane. With preopson-
ized staphylococci in the absence of serum, PG-APS did not
interfere with bacterial attachment (Fig. 5). When preopson-
ized bacteria were added to PMN preparations in the pres-
ence of 50 p,g of PG-APS per ml and 10% serum, a 42%
inhibition of attachment (P < 0.025) was observed (Fig. 5).
This effect persisted even after cells exposed to PG-APS and
serum were vigorously washed (Fig. 5). No inhibition of
attachment was observed, however, when PMNs were incu-
bated with heat-treated serum and 50 jig of PG-APS per ml












PMN 100 ,jg 50 jig 10 jg I 9g
Cont L PG-APS/ml
FIG. 3. Concentrations of PG-APS greater than 10 pLg/ml inhibit-
ed PMN phagocytosis of "4C-labeled S. aureus compared with the
control. Normal serum (10%) was added before bacteria. Bars
represent the mean and brackets represent the standard deviation of
the number of experiments shown in parentheses. Experiments
were performed in duplicate.
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40 - importance at tissue sites where such exposure is chronic,
PMN either because offrequent reinfection or because the antigen
(N- 2) cannot be eliminated. PG-APS can be isolated from tissue
30 for long periods after inoculation (24) and can initiate perio-dontitis after injection into rat gingiva (11). It seems possible
that the interaction of PG-APS with PMNs may initiate or
20
-
promote this process of inflammation.
20 ~ ,/ / In the present study we have shown that PG-APS in the
---4~~ 5Opg9/mI presence of serum inhibits killing of S. aureus by human
PG-APS neutrophils. These observations could not be attributed to
10 >__~ (N 2) PG-APS cytotoxicity. We have recently demonstrated that
through the action of the complement cascade, PG-APS
stimulates a low level of release of 02 reduction products by
,, , , , , PMNs (13). Because of the importance of 02 reduction
0 10 20 30 40 50 60 products for the killing of S. aureus (31), experiments were
performed to exclude the possibility that the microbicidal
MINUTES defect observed was due to PMN "exhaustion." Although
IG. 4. Phagocytosis of "4C-labeled S. aureus by PMNs in the opsonized zymosan incubated in the presence of PG-APS
ience and absence of PG-APS. All preparations contained 10% failed to cause normal stimulation of PMNs, no such inhibi-
mal serum. Points represent the results of duplicate prepara- tion was observed when PMA was used. These results
Is. This experiment is typical of three others. suggest that decreased (complement-mediated [21]) binding
of opsonized zymosan to PMNs interfered with optimal
teria (Fig. 5). These results suggest that even when S. metabolic stimulation, although the cells were clearly capa-
eus cells are adequately opsonized, there appears to be ble of such stimulation when a serum-independent agent
ipetition with PG-APS for binding sites on the PMN (e.g., PMA) was used.
nbrane. PG-APS appears to be opsonized with heat- Consistent with this hypothesis, we observed a decrease
le components in serum. in the binding of 14C-labeled S. aureus to cells treated with
DISCUSSION PG-APS and 10% normal serum. This inhibition was identi-
cal in magnitude to the killing defect observed and required
acterial degradation products may have an impact on the similar concentrations of PG-APS.
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FIG. 5. Effect of 50 ,ug of PG-APS per ml on PMN phagocytosis of preopsonized S. aureus. Open bars represent PMNs alone, and hatched
bars represent PMNs incubated with 50 ,ug of PG-APS per ml. In some experiments, PMNs were incubated with serum and PG-APS for 30
min and then washed twice before bacteria were added. Bars represent the mean and brackets represent the standard deviation of the number
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which PG-APS might interfere with PMN uptake of S.
aureus. Greenblatt and co-workers have reported activation
of the complete cascade by peptidoglycan and cell wall
preparations of group A streptococci (10), implying that
bacterial attachment to PMNs could be inhibited by deple-
tion of complement components essential for bacterial opso-
nization (14). However, our studies with preopsonized S.
aureus demonstrated a competition for binding sites on the
PMN membrane with PG-APS in the presence of serum.
Although inhibition of bacterial uptake could not be reversed
by washing cells after PG-APS had an opportunity to bind,
heating serum to inactivate complement components elimi-
nated the effects of PG-APS. This result is entirely consis-
tent with a recent report by Pryzwansky et al., which
demonstrated opsonization of PG-APS by C3b; binding was
not observed in the absence of serum or when heat-inactivat-
ed serum was used (20).
Inhibition of phagocytosis by bacterial peptidoglycan was
reported previously. Smialowicz and Schwab noted de-
creased uptake of latex particles by rat peritoneal macro-
phages in culture after exposure to PG-APS (27). Employing
peptidoglycan isolated from S. aureus, Musher and co-
workers noted inhibition of both PMN chemotaxis and
phagocytosis (16). In neither of these studies were the
inhibitory effects dependent on serum. However, experi-
mental differences in peptidoglycan preparation (e.g., staph-
ylococcal versus streptococcal [16]) and the target particle
(e.g., latex versus staphylococci [27]) make comparisons
difficult.
Recently, Shurin and co-workers reported defective PMN
function in two patients with capnocytophaga infection and
demonstrated that sonic extracts of these bacteria inhibited
PMN polarization and chemotaxis (26), implying a mecha-
nism by which capnocytophaga might produce severe perio-
dontisis. Streptococcal species are generally isolated from
early supragingival plaque (28). Our studies suggest that PG-
APS from these bacteria may also inhibit phagocyte func-
tion, thereby allowing replication of the complex microflora
associated with chronic periodontitis (18, 28).
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